Read by QxMD icon Read

Therapeutic Delivery

Loveleen Kaur, Inderbir Singh
Novel modified pharmaceutical materials with desired functionalities are required for the development of drug delivery systems. Excipients are no more inert ingredients but these are playing crucial roles in modifying physicochemical properties of drugs and for imparting desired functionalities in the delivery system. In this review article, modified materials such as grafted, composite and coprocessed have been discussed along with the updated reported literature on the same. Applications of grafted materials as drug release retardant, mucoadhesive polymer and tablet superdisintegrant have been elaborated...
November 17, 2016: Therapeutic Delivery
Mariacristina Gagliardi
With the refinement of functional properties, the interest around biodegradable materials, in biorelated applications and, in particular, in their use as controlled drug-delivery systems, increased in the last decades. Biodegradable materials are an ideal platform to obtain nanoparticles for spatiotemporal controlled drug delivery for the in vivo administration, thanks to their biocompatibility, functionalizability, the control exerted on delivery rates and the complete degradation. Their application in systems for cancer treatment, brain and cardiovascular diseases is already a consolidated practice in research, while the bench-to-bedside translation is still late...
November 11, 2016: Therapeutic Delivery
David J Brayden
David Brayden speaks to Hannah Makin, Commissioning Editor: David Brayden is a Full Professor (Advanced Drug Delivery) at the School of Veterinary Medicine, University College Dublin (UCD) and also a Fellow of the UCD Conway Institute. Following a PhD in Pharmacology at the University of Cambridge, UK (1989), and a postdoctoral research fellowship at Stanford University, CA, USA, he set up Elan Biotechnology Research's in vitro pharmacology laboratory in Dublin (1991). At Elan, he became a senior scientist and project manager of several of Elan's joint-venture drug delivery research collaborations with US biotech companies...
November 8, 2016: Therapeutic Delivery
Iain Simpson
No abstract text is available yet for this article.
November 8, 2016: Therapeutic Delivery
Serap Yalçın, Özlem Özlüer, Ufuk Gündüz
Development of novel drug-delivery systems aims to specifically deliver anticancer drugs to tumor tissues and improve the efficiency of chemotherapy, while minimizing side effects of drugs on healthy tissues and organs. However, drug-delivery systems are confronted by membrane barriers and multiple drug resistance in cancer cells. In recent years, the obtained results indicate an important role of lipids, proteins and carbohydrates in apoptosis, drug transport and the process of cellular uptake of nanoparticles via endocytosis...
October 28, 2016: Therapeutic Delivery
Guilherme M Gelfuso, Marcílio Ss Cunha-Filho, Tais Gratieri
No abstract text is available yet for this article.
October 28, 2016: Therapeutic Delivery
Acm Saúde, O L Franco
The resistance of infectious bacteria to current antibiotics is a worldwide problem caused, partially, by the overuse of antimicrobials. The use of nanotechnology as an innovative tool against bacterial infections provides a range of methodologies to redesign old antibiotics for novel and remarkable new strategies. Thus, functionalized antibiotics present structures with improved bioavailability, low toxicity and specificity to bacterial membrane. In this context, this review will describe the use of nanotechnology as an innovative tool to functionalize antibiotics...
October 28, 2016: Therapeutic Delivery
Jennifer Cheung, Takahiro Chino, Cynthia Co, Krystyna Konopka, Nejat Düzgüne
AIM: Viral vectors are used commonly in gene therapy trials, but their potential toxic effects are a serious concern. Identification of highly efficient nonviral vectors may alleviate these effects. Results & methodology: We compared the abilities of TransfeX, TransIT-LT1 and adenovirus to deliver the firefly luciferase and green fluorescent protein genes into HeLa cervical carcinoma, and HSC-3 and H357 oral squamous cell carcinoma cells. TransfeX mediated fourfold higher gene expression in HeLa cells than adenovirus, even at the highest multiplicity of infection...
October 28, 2016: Therapeutic Delivery
Narendar Dudhipala, Kishan Veerabrahma
Candesartan cilexetil (CC), an antihypertensive drug, has low oral bioavailability due to poor solubility and hepatic first-pass metabolism. These are major limitations in oral delivery of CC. Several approaches are known to reduce the problems of solubility and improve the bioavailability of CC. Among various approaches, nanotechnology-based delivery of CC has potential to overcome the challenges associated with the oral administration. This review focuses on various nano-based delivery systems available and tried for improving the aqueous solubility, dissolution and consequently bioavailability of CC upon oral administration...
February 2017: Therapeutic Delivery
Serena Mazzucchelli, Fabio Corsi
No abstract text is available yet for this article.
February 2017: Therapeutic Delivery
Iain Simpson
This Industry Update covers the period from 1 October through to 31 October 2016, and is based on information sourced from company press releases, scientific literature, patents and various news websites. The month saw several news items covering drug-delivery devices, including a new sensor to monitor and support the use of inhalers; launch in the UK of a new autoinjector for Cimzia(®), UCB's rheumatoid arthritis drug; and approval of Roche's Lucentis(®) in a prefilled syringe. Research was also published to show the value of continuous blood pressure monitoring in dementia management...
February 2017: Therapeutic Delivery
Chase S Linsley, Benjamin M Wu
The convergence of wearable sensors and personalized medicine enhance the ability to sense and control the drug composition and dosage, as well as location and timing of administration. To date, numerous stimuli-triggered smart drug-delivery systems have been developed to detect changes in light, pH, temperature, biomolecules, electric field, magnetic field, ultrasound and mechanical forces. This review examines the major advances within the last 5 years for the three most common light-responsive drug delivery-on-demand strategies: photochemical, photoisomerization and photothermal...
February 2017: Therapeutic Delivery
Teófilo Vasconcelos, Sara Marques, Bruno Sarmento
The increasing number of new chemical entities is bringing new challenges to the field of drug delivery. These drugs present bioavailability issues that are frequently associated with intestinal metabolism or efflux mechanisms. Some excipients, particularly surfactants, have demonstrated a capacity to interfere with these mechanisms, improving drug bioavailability. Consequently, these excipients can no longer be considered as inert and should be subject to special considerations from a regulatory perspective...
February 2017: Therapeutic Delivery
Sarah Shigdar
No abstract text is available yet for this article.
February 2017: Therapeutic Delivery
Tarun Goswami
Tarun Goswami speaks to Hannah Makin, Commissioning Editor: Tarun Goswami obtained his BS (Pharmacy) in 2003 from Delhi University (India) and his PhD in Pharmaceutical Sciences in 2008 from the University of the Pacific (CA, USA). He currently works at Amneal Pharmaceuticals as a Formulation Scientist in the Transdermal Drug Delivery Group. Having published multiple abstracts and articles in the area of transdermal and oral mucosal drug delivery, his current interests include the development of drug products that are administered via alternate routes such as through the skin and oral mucosa...
January 2017: Therapeutic Delivery
Jessica E Pullan, Austin T Pullan, V Bryce Taylor, Benjamin D Brooks, Daniel Ewert, Amanda E Brooks
Sequestra, present in many cancers and orthopedic infections, provide a safe harbor for the development of drug resistance. In the face of burgeoning drug resistance, the importance of nanoscale, microenvironment-triggered drug delivery cannot be overestimated. Such strategies may preserve pharmaceutical efficacy and significantly alter the etiology of many orthopedic diseases. Although temperature-, pH- and redox-responsive nanoparticle-based systems have been extensively studied, local drug delivery from polymeric nanoparticles can be triggered by a variety of energy forms...
January 2017: Therapeutic Delivery
Brahmeshwar Mishra, Sundeep Chaurasia
Oral delivery of cancer chemotherapeutic drugs (CCDs) is subject matter in the 21st century, which changes the dosage regimens of oncotherapy with enhancement in patient's life and deducts the cost of therapy. The present report explored on the nano-oncology such as polymeric nanoparticles (PNPs) as an oral CCDs delivery vehicle, showing great potential for colon cancer treatment. Proof-of-concept in vitro and in vivo results for delivery of CCDs using various oral PNPs are included in this review from the literatures...
January 2017: Therapeutic Delivery
Eli J Curry, Atta D Henoun, Albert N Miller, Thanh D Nguyen
Recently, there has been an emerging interest in controlling 3D structures and designing novel 3D shapes for drug carriers at nano- and micro-scales. Certain 3D shapes and structures of drug particles enable transportation of the drugs to desired areas of the body, allow drugs to target specific cells and tissues, and influence release kinetics. Advanced nano- and micro-manufacturing methods including 3D printing, photolithography-based processes, microfluidics and DNA origami have been developed to generate defined 3D shapes and structures for drug carriers...
January 2017: Therapeutic Delivery
Michele Herneisey, Jonathan Williams, Janja Mirtic, Lu Liu, Sneha Potdar, Christina Bagia, Jane E Cavanaugh, Jelena M Janjic
AIM: Delivery of the natural anti-inflammatory compound resveratrol with nanoemulsions can dramatically improve its tissue targeting, bioavailability and efficacy. Current assessment of resveratrol delivery efficacy is limited to indirect pharmacological measures. Molecular imaging solves this problem. Results/methodology: Nanoemulsions containing two complementary imaging agents, near-infrared dye and perfluoropolyether (PFPE), were developed and evaluated. Nanoemulsion effects on macrophage uptake, toxicity and NO production were also evaluated...
December 2016: Therapeutic Delivery
Tsontcho Ianchulev, Arturo Chayet, Malik Kahook, Mark Packer, Louis Pasquale, Robert N Weinreb
AIM: Eyedroppers deliver medication volumes exceeding conjunctival absorptive capacity, causing spillage and risking ocular/systemic complications. We evaluated piezoelectric microdosing. Results/methodology: Subjects (n = 102) received precision microdroplet delivery of phenylephrine (2.5%) and tropicamide (1.0%): 1 × 1.5 μl, 1 × 6 μl or 2 × 3 μl of each (randomized 1:1:1), into one eye. Contralateral eyes received eyedropper doses of both drugs. Outcomes were pupil dilation (0-60 min) and patient satisfaction...
October 13, 2016: Therapeutic Delivery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"